Etrolizumab outperforms placebo in achieving clinical remission for Crohn's disease
Written By : Dr.Niharika Harsha B
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2022-10-19 14:45 GMT | Update On 2022-10-19 14:45 GMT
Advertisement
| Maintenance phase TEA | etrolizumab, n=217 | Placebo, n=217 |
| Injection site erythema | 6 | 14 |
| Arthralgia | 5 | 8 |
| Headache | 5 | 7 |
- The most common serious adverse event was an exacerbation of Crohn's disease seen in 14 [6%] of 217 patients taking a placebo and four [2%] of 217 patients taking 105 mg etrolizumab in the maintenance cohort.
Thus, the trial revealed that etrolizumab was successful in attaining clinical remission and endoscopic improvement in a significantly higher proportion of patients with moderately to severely active Crohn's disease during the maintenance phase but the same could not be achieved during the induction phase.
Further reading: https://doi.org/10.1016/S2468-1253(22)00303-X
Sandborn WJ, Panés J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomized, placebo-controlled, double-blind, phase 3 trial [published online ahead of print, 2022 Oct 11]. Lancet Gastroenterol Hepatol. 2022; S2468-1253(22)00303-X.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.